container

New Research Looking at The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes

US Endocrinology, the peer-reviewed journal, publish thought-provoking article by Priscilla Hollander on The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
The prevalence of diabetes continues to rise, following the rising rates of obesity.

(PRWEB UK) 3 June 2014

US Endocrinology, the peer-reviewed journal, publish thought-provoking article by Priscilla Hollander on The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes.

The prevalence of diabetes continues to rise, following the rising rates of obesity. Obesity is not only associated with an increased risk for developing type 2 diabetes but also an elevated probability of developing long-term complications associated with the disease. Weight gain is also an important concern as a potential side effect of therapies that improve glycemic control in diabetes, including insulin therapy. As a result, patients with type 2 diabetes are at risk for a vicious circle of increasing weight and increasing insulin resistance, thus requiring further intensification of glycemic treatment. It is therefore important to address the problem of obesity in patients with type 2 diabetes. In 2012, the US Food and Drug Administration (FDA) approved two new anti-obesity medications: lorcaserin and phentermine/topiramate extended-release. Both agents have demonstrated clinically meaningful weight reduction as well as significant improvements in glycemic control in obese patients with diabetes. Liraglutide has also shown weight loss and improvements in glycemic control in patients with diabetes. Anti-obesity drugs, in conjunction with lifestyle changes, may play a valuable role in the management of diabetes.

To continue reading this peer-reviewed article in full for free please go to: http://www.touchendocrinology.com/articles/role-anti-obesity-drugs-patients-type-2-diabetes

NOTE TO EDITORS
touchENDOCRINOLOGY (a division of Touch Medical Media) provides independent, cutting-edge, peer-reviewed content from world renowned physicians, designed to lead the debate on health and to engage, inform, and support physicians in improving patient outcomes globally.

touchENDOCRINOLOGY.com provides an international platform for peer-reviewed content from industry-leading journals alongside other carefully selected sources and aims to support physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity within the field of diabetes.

Our portfolio of peer-reviewed journals, European Endocrinology and US Endocrinology comprise of concise review articles which are designed to keep busy physicians up-to-date with the latest developments in their field and serve as a key reference resource for the international diabetes community.

http://www.touchendocrinology.com


Contact